GlassScriptPhysician profile
Paul M Tender
NPI 1326159088
$1,043.70
in general payments reported to CMS, 2019-2025
20 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $66.73 · 2021: $64.13 · 2022: $61.34 · 2023: $210 · 2024: $206 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573 · Education: $19.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.76 |
| Education | $19.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $206.73 | 2023-2025 | Stravix Pl, Renasys Touch, Pico |
| Intuitive Surgical, INC. | $177.96 | 2023-2024 | Da Vinci Surgical System |
| Medical Device Business Services, INC. | $110.94 | 2019 | |
| Abbvie INC. | $95.67 | 2019-2020 | |
| Ethicon US, LLC | $79.97 | 2021-2024 | Echelon; Endopath |
| Baxter Healthcare | $61.57 | 2023-2024 | Seprafilm, Perclot |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.30 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.92 | 2019-2020 | |
| Coloplast Corp | $31.04 | 2022 | |
| Medtronic, INC. | $30.30 | 2022 | |
| Boston Scientific Corporation | $23.66 | 2025 | Axonics |
| Braintree Laboratories, INC. | $21.22 | 2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $20.53 | 2019 | |
| Otto Bock Healthcare LP | $19.45 | 2024 | |
| Merck Sharp & Dohme LLC | $18.57 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $18.33 | 2025 | Myrisk |
| Depuy Synthes Sales INC. | $16.75 | 2023 | Monovisc, Orthovisc |
| Pacira Pharmaceuticals Incorporated | $15.59 | 2024 | Exparel |
| Averitas Pharma INC. | $15.11 | 2024 | Qutenza |
| Ipsen Biopharmaceuticals, INC | $15.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Tender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.